Stockreport

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF – Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN [Read more]